ArticleProceedings of the National Academy of Sciences of the United States of America2015
Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors.Cell reports. Medicine · 2026Article
- Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy.Nature biomedical engineering · 2026Article
- Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases.Precision clinical medicine · 2026Review
- Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method.Nature biotechnology · 2025Article
- Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.Immunotherapy · 2025Review
- Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy.Cell reports methods · 2024Article
- Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.Current pharmaceutical biotechnology · 2024Review
- Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering.Nature communications · 2023Article
- Advancing cell-based cancer immunotherapy through stem cell engineering.Cell stem cell · 2023Review
- Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy.Frontiers in medicine · 2023Review
- Article
- Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention.Stem cell research & therapy · 2022Article
- Novel Immunotherapies for Osteosarcoma.Frontiers in oncology · 2022Review
- Review
- Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.Cell reports. Medicine · 2021Article
- Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.Cellular & molecular immunology · 2021Review
- Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.Nature communications · 2021Article
- Methods for Studying Mouse and Human Invariant Natural Killer T Cells.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Creatine uptake regulates CD8 T cell antitumor immunity.The Journal of experimental medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Invariant natural killer T (iNKT) cells comprise a small population of αβ T lymphocytes. They bridge the innate and adaptive immune systems and mediate strong and rapid responses to many diseases, including cancer, infections, allergies, and autoimmunity. However, the study of iNKT cell biology and the therapeutic applications of these cells are greatly limited by their small numbers in vivo (∼0.01-1% in mouse and human blood). Here, we report a new method to generate large numbers of iNKT cells in mice through T-cell receptor (TCR) gene engineering of hematopoietic stem cells (HSCs). We showed that iNKT TCR-engineered HSCs could generate a clonal population of iNKT cells. These HSC-engineered iNKT cells displayed the typical iNKT cell phenotype and functionality. They followed a two-stage developmental path, first in thymus and then in the periphery, resembling that of endogenous iNKT cells. When tested in a mouse melanoma lung metastasis model, the HSC-engineered iNKT cells effectively protected mice from tumor metastasis. This method provides a powerful and high-throughput tool to investigate the in vivo development and functionality of clonal iNKT cells in mice. More importantly, this method takes advantage of the self-renewal and longevity of HSCs to generate a long-term supply of engineered iNKT cells, thus opening up a new avenue for iNKT cell-based immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.